The FDA on November 16, 2017, granted regular approval to GAZYVA® in combination with chemotherapy, followed by GAZYVA® monotherapy, in patients achieving at least a Partial Remission, for the treatment of adult patients with previously untreated Stage II bulky, III, or IV Follicular Lymphoma (FL). GAZYVA® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
